Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Pfizer terminated NMIBC trial due to strategic consideration
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(703)
•••
Comment by IvanVanBeethovenon Dec 23, 2022 6:58am
340 Views
Post# 35188941

RE:RE:RE:RE:Pfizer terminated NMIBC trial due to strategic consideration

RE:RE:RE:RE:Pfizer terminated NMIBC trial due to strategic considerationHi Cainplap,

I have to tell you otherwise. A friend of mine wanted to participate in the PP and sent an email in early November with this question to both Theralase and Research Capital Corporation. However, he received no response. Apparently, one was not interested!

CAinPlap wrote: Good post!! Only issue I have is let's be honest and say there was insufficient interest in the 2nd round of the PP. i.e they did not turn any money away.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities